Guselkumab Potentially Increases Treatment Choices For Psoriasis Interview with:

Prof. Dr. med. Kristian Reich Dermatologie, Allergologie Psoriasis- und Neurodermitis-Trainer Hamburg

Prof.  Kristian Reich

Prof. Dr. med. Kristian Reich
Dermatologie, Allergologie
Psoriasis- und Neurodermitis-Trainer
Hamburg What is the background for this study? What are the main findings?

Response: Ustekinumab is an antibody against the p40 molecule shared by IL-12 and IL-23. The antibody shows a favorable benfit-risk profile in the treatment of psoriasis. IL-23 is regarded a key driver in psoriasis pathology. It is speculated that antibodies against the IL-23-specific subunit p19 may produce even higher levels of clinical response than ustekinumab or the anti-TNF antagonist adalimumab. Guselkumab is the first IL-23p19 antibody to publish phase III data in psoriasis. What should readers take away from your report?

Response: Treatment of patients with moderate-to-severe plaque-type psoriasis with guselkumab induced a rapid onset of response and high levels of clear or almost clear skin. The percentage of patients achieving PASI90 (approximately 75%) and PASI100 (approximately 40%) responses at week 24 were significantly higher than those seen with adalimumab therapy. What recommendations do you have for future research as a result of this study?

Response: Guselkumab injections were given at baseline, week 4 and every 8 weeks thereafter in the voyage phase III trials. The convenient injection scheme and the observed high response levels indicate that IL-23p19 inhibitors such as guselkumab have the potential to broaden the therapeutic armamentarium of psoriasis. Patients may benefit from more individualized dosing schemes based on their individual clinical response.

Disclosures: Prof. Reich has received honoraria as speaker and/or participant in advisory boards from Janssen, the manufacturer of guselkumab and participated in clinical trials with guselkumab. Thank you for your contribution to the community.


Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Reich, Kristian et al.
Journal of the American Academy of Dermatology , Volume 76 , Issue 3 , 418 – 431

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on




Last Updated on February 24, 2017 by Marie Benz MD FAAD